Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Salud colect ; 17: e3246, 2021. tab, graf
Article in Spanish | LILACS | ID: biblio-1290035

ABSTRACT

RESUMEN En abril de 2016, el Instituto Nacional de Servicios Sociales para Jubilados y Pensionados excluyó del subsidio social la cobertura al 100% de 159 fármacos, entre ellos, los antiartrósicos sintomáticos de acción lenta o symptomatic slow-acting drugs for osteoarthritis (SySADOA), por insuficiente evidencia de beneficio clínico significativo. Evaluamos el efecto de esta medida sobre la utilización de SySADOA y de los antiinflamatorios no esteroides (AINE), no afectados por la medida. Se compararon las dispensas ambulatorias de los SySADOA y los AINE de 2015 a 2017, midiendo unidades dispensadas, precio de venta al público y gasto de bolsillo del beneficiario para cada mes. Luego de la medida, descendieron un 61,6% los envases de SySADOA dispensados y un 63,4% el monto total del precio de venta al público, medido en valores constantes. La dispensa no se reorientó hacia los AINE, que descendieron un 6,1%. Disminuyó tanto la incidencia de nuevos tratamientos (de 6,4 a 3,3 tratamientos por 1.000 beneficiarios por mes) como su continuidad. El gasto de bolsillo de los beneficiarios en SySADOA aumentó un 75,8% (a valores constantes). La desinversión en intervenciones de valor terapéutico cuestionable es una herramienta valiosa para la sustentabilidad de los sistemas de salud.


ABSTRACT In April 2016, the National Institute of Social Services for Retirees and Pensioners discontinued its policy of 100% coverage for 159 drugs (the "social subsidy"), including symptomatic slow-acting drugs for osteoarthritis (SYSADOAs), due to insufficient evidence of significant clinical benefit. We evaluated the effect of this measure on the use of SYSADOAs as well as non-steroidal anti-inflammatory drugs (NSAIDs), which were unaffected by this policy change. We compared outpatient dispensations of SYSADOAs and NSAIDs from 2015 to 2017, measuring dispensed units, retail price, and out-of-pocket expenses for beneficiaries each month. After the change in coverage, there was a 61.6% total decrease in SYSADOA units dispensed, and a 63.4% decrease in the final sales price to the public, measured in constant values. Dispensation was not reoriented towards NSAIDs, which fell by 6.1%. The incidence of new treatments decreased (from 6.4 to 3.3 treatments per 1,000 beneficiaries per month), as did their continuity. Beneficiaries' out-of-pocket spending on SYSADOAs increased by 75.8% (at constant values). Disinvestment in interventions with questionable therapeutic value is an important tool in working toward the sustainability of health systems.


Subject(s)
Humans , Osteoarthritis/drug therapy , Pharmaceutical Preparations , Argentina , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Glucosamine/therapeutic use
2.
Adv Rheumatol ; 61: 7, 2021. tab, graf
Article in English | LILACS | ID: biblio-1152749

ABSTRACT

Abstract Objectives: To compare the efficacy and safety of a new formulation of a fixed dose combination of glucosamine sulfate (GS; 1500 mg) and bovine chondroitin sulfate (CS; 1200 mg) versus the reference product (RP) in patients with knee osteoarthritis (OA). Methods: In this multicenter, randomized, single-blind trial, 627 patients with knee osteoarthritis (OA)—Kellgren-Lawrence grades 2 or 3 and mean score ≥ 40 mm in the WOMAC pain subscale—were randomized to receive GS/ CS or the RP for 24 weeks. The primary efficacy endpoint was the absolute change in WOMAC pain subscale score. The secondary endpoints included the following: WOMAC total and subscale scores, overall assessment of the disease by the patient and the investigator, SF-12 score, OMERACT-OARSI response rate to the treatment, and rescue medication use. Results: Mean reductions of WOMAC pain score were - 35.1 (sd = 23.2) mm in the GS/CS group and - 36.5 (sd = 24.9) mm in the RP group. The difference between the adjusted means of both treatments confirmed the noninferiority of GS/CS versus the RP. Improvement was observed in pain, stiffness, physical function and total WOMAC score, as well as in overall OA assessment by the patient and the investigator for both groups. No improvement was observed in SF-12. The rate of OMERACT-OARSI responders was 89.4% in GS/CS group and 87.9% in the RP group. Headache and changes in glucose tolerance were the most frequent treatment-related adverse events. Conclusions: The new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin sulfate was non-inferior to the RP in symptomatic treatment of knee OA, with a high responder rate and good tolerability profile. Trial registration: ClinicalTrials.gov; Registration number NCT02830919; Date of registration: July 13, 2016; First randomization date: December 05, 2016).(AU)


Subject(s)
Humans , Chondroitin/therapeutic use , Osteoarthritis, Knee/drug therapy , Drug Combinations , Glucosamine/therapeutic use , Single-Blind Method , Treatment Outcome
3.
Braz. arch. biol. technol ; 63: e20180687, 2020. tab, graf
Article in English | LILACS | ID: biblio-1142497

ABSTRACT

Abstract Glucosamine is known as anti-inflammatory, antioxidant and as neuroprotective as well as using to treat many of diseases. This work aimed to investigate the remedial effect of glucosamine (20mg/kg b.wt) against the damage induced by a single dose of γ-radiation (8Gy) or aluminium chloride (AlCl3) (100mg/kg b.wt) in the heart and brain tissues of female rats. Serum aspartate aminotransferase (AST), cholesterol, triglycerides (TGs), LDH and creatine kinase (CPK) were measured. Moreover, gene expression of amyloid protein precursor (APP) and seladin-1 were estimated in the brain tissue. Also, acetylcholinesterase activity (AChE) and p-tau protein expression were estimated in brain homogenate. Metallothioneine (MT) was estimated in the heart and brain tissues. Heart and brain histopathological examination was performed. Irradiation significantly decreased serum AST, CPK and LDH, as well as MT levels in heart and brain tissues. Also, gene expression of seladin-1 decreased. On the other hand, irradiation significantly increased serum TGs level and brain AchE activity, tau protein, and β-amyloid percursor (APP). AlCl3 administration (21 days) induced disturbance in most of the estimated parameters, especially AST, TGs, and MT. Glucosamine treatment with irradiation or AlCl3 improved most of the measured parameters. In addition, histopathological examination confirmed the biochemical results. In conclusion: Glucosamine could be used to improve the heart and brain damages induced by γ-radiation exposure or AlCl3.


Subject(s)
Animals , Female , Rats , Brain Diseases/drug therapy , Cardiovascular Diseases/drug therapy , Radiation Exposure/adverse effects , Aluminum Chloride/adverse effects , Glucosamine/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Brain Diseases/etiology , Brain Diseases/pathology , Cardiovascular Diseases/etiology , Cardiovascular Diseases/pathology , Polymerase Chain Reaction , Rats, Wistar , Disease Models, Animal
4.
Clinics ; 74: e722, 2019. tab, graf
Article in English | LILACS | ID: biblio-1001822

ABSTRACT

OBJECTIVES: This study aimed to provide evidence for understanding how to treat osteoarthritis (OA) in our country. Therefore, it was necessary to match information and investigations related to the treatment of the disease from the three main types of specialists involved: physiatrists, orthopedists and rheumatologists. METHODS: The authors acted as a scientific advisory committee. From the initial discussions, a structured questionnaire was developed for use with a group of specialists on OA using the Delphi technique. The questionnaire was sent to 21 experts appointed by the authors, and the results obtained were critically analyzed and validated. RESULTS: The prevalence of OA was 33% in Brazil, corresponding to one-third of the individuals in the reference population, which included individuals over 25 years of age. Another significant finding was that most patients did not receive any form of treatment in the early stages of OA. CONCLUSION: The committee pointed to the need for early intervention and that the available medicinal resources can fulfil this important role, as is the case with SYSADOA treatments. Glucosamine-based medicinal products with or without chondroitin could also fulfill this need for early treatment. The other generated evidence and included investigations were then grouped together and are the subject of this publication.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Osteoarthritis/therapy , Delphi Technique , Clinical Competence/standards , Evidence-Based Medicine/standards , Orthopedics/standards , Osteoarthritis/drug therapy , Physical and Rehabilitation Medicine/standards , Severity of Illness Index , Brazil , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Chondroitin Sulfates/therapeutic use , Treatment Outcome , Osteoarthritis, Knee/therapy , Consensus , Drug Therapy, Combination , Glucosamine/therapeutic use
6.
Arq. bras. med. vet. zootec ; 67(2): 325-333, Mar-Apr/2015. tab, ilus
Article in English | LILACS, VETINDEX | ID: lil-747063

ABSTRACT

Chondroitin and glucosamine sulfate nutraceuticals are commonly used in the management of degenerative articular disease in veterinary routine. However, there are controversies on the contribution of these substances to articular cartilage. The purpose of this study was to evaluate the efficiency of a chondroitin and glucosamine sulfate-based veterinary nutraceutical on the repair of an induced osteochondral defect in a dog femoral condyle, by macroscopic, histological and histomorphometric analyses. The nutraceutical was orally administered the day following injury induction, every 24 hours (treated group, TG, n=24), compared with animals that did not receive the product (control group, CG, n=24). Six animals per group were anaesthetized for sample collection at 15, 30, 60 and 90 days after surgery. At 15 days, defects were macroscopically filled with red-pinkish tissue. After 30 days, whitish color tissue was observed, both in TG and CG animals, with firmer consistency to touch at 60 and 90 postoperative days. Histological analysis demonstrated that, in both groups, there was initial blood clot formation, which was subsequently substituted by a fibrin net, with capillary proliferation from the adjacent bone marrow and infiltration of mesenchymal cells in clot periphery. As cellular differentiation developed, repair tissue presented a fibrocartilage aspect most of the time, and new subchondral bone formation occurred in the deepest area corresponding to the defect. Histomorphometry suggested that the nutraceutical did not favor the articular cartilage repair process. It was concluded that nutraceutical did not significantly influence chondrocytes proliferation or hyaline architecture restoration.(AU)


Os nutracêuticos compostos de sulfato de condroitina e glucosamina são comumente utilizados no manejo da doença articular degenerativa na rotina veterinária. Entretanto, existem controvérsias sobre a contribuição dessas substâncias à cartilagem articular. O objetivo deste trabalho foi avaliar a eficácia de um nutracêutico veterinário à base de sulfato de condroitina e glucosamina na reparação de defeitos osteocondrais induzidos no côndilo femoral de cães, através de análises macroscópica, histológica e histomorfométrica. O nutracêutico foi administrado no dia seguinte à indução da lesão, pela via oral, a cada 24 horas (grupo tratado - GT, 24 animais), sendo comparado a animais que não receberam o produto (grupo controle - GC, de igual número de animais). Aos 15, 30, 60 e 90 dias após a cirurgia, seis animais por grupo foram anestesiados para ser realizada a coleta das amostras. Aos 15 dias, os defeitos eram macroscopicamente preenchidos por tecido de coloração rósea a avermelhada. Já a partir dos 30 dias, observou-se preenchimento por tecido de coloração esbranquiçada, tanto nos animais do GT quanto nos do GC, com consistência mais firme ao toque digital aos 60 e 90 dias de pós-operatório. A análise histológica revelou que, em ambos os grupos, houve inicialmente formação de coágulo sanguíneo que, posteriormente, foi substituído por uma rede de fibrina, com proliferação de capilares a partir da medula óssea adjacente e infiltração de células mesenquimais na periferia do coágulo. À medida que se processou a diferenciação celular, o tecido de reparação se apresentou na maioria das vezes com aspecto de fibrocartilagem e, na região mais profunda da área correspondente ao defeito, ocorreu formação de osso novo subcondral. A histomorfometria sugeriu que o nutracêutico não favoreceu o processo de reparação da cartilagem articular. Concluiu-se que o nutracêutico não influenciou consideravelmente na proliferação de condrócitos nem na restauração da arquitetura hialina.(AU)


Subject(s)
Animals , Dogs , Osteoarthritis/veterinary , Cartilage Diseases/veterinary , Chondroitin Sulfates/therapeutic use , Arthroplasty, Subchondral/veterinary , Glucosamine/therapeutic use , Joint Diseases/veterinary
7.
Evid. actual. práct. ambul ; 12(1): 28-30, ene.-mar. 2009.
Article in Spanish | LILACS | ID: lil-569757

ABSTRACT

La osteoartritis es una enfermedad degenerativa del cartílago que produce disminución del espacio articular y cambios en el hueso subyacente. Se postula que la administración de glucosamina exógena estimularía la síntesis de matriz cartilaginosa y protegería el hueso. A pesar de esto, no hay evidencia sólida para sostener el uso de glucosamina en la osteoartritis leve.


Subject(s)
Humans , Male , Female , Pain/drug therapy , Glucosamine/pharmacology , Glucosamine/therapeutic use , Osteoarthritis/diagnosis , Osteoarthritis , Osteoarthritis/drug therapy , Osteoarthritis/therapy , Therapeutics
9.
Rev. Círc. Argent. Odontol ; 65(203): 6-10, jun. 2008. ilus
Article in Spanish | LILACS | ID: lil-508529

ABSTRACT

El desplazamiento discal en la articulación temporomandibular es una afección habitual. En algunos casos, el disco desplazado sin reducción, puede producir, si la manifestación ocurre durante el período de crecimiento, alteraciones de desarrollo cóndilo mandibular, tales como asimetrías y disminución del tamaño de esas estructuras a partir de procesos degenerativos a nivel condilar. Estos hechos han sido observados en otros estudios de los que se hace una breve reseña. A continuación se presentan dos casos clínicos en pacientes con DDsR, proceso degenerativo condilar, alteración de crecimiento y asimetría.


Subject(s)
Humans , Male , Adult , Animals , Facial Asymmetry/etiology , Mandibular Condyle/abnormalities , Mandibular Condyle/growth & development , Intervertebral Disc Displacement/complications , Intervertebral Disc Displacement/etiology , Temporomandibular Joint Disc/abnormalities , Anti-Inflammatory Agents, Non-Steroidal , Temporomandibular Joint/physiopathology , Glucosamine/therapeutic use , Magnetic Resonance Imaging/methods , Maxillofacial Development , Occlusal Splints , Chondroitin Sulfates/therapeutic use , Tomography, X-Ray Computed/methods
10.
Clinics ; 61(5): 461-466, Oct. 2006. ilus, tab, graf
Article in English | LILACS | ID: lil-436771

ABSTRACT

PURPOSE: The purpose of this study was to compare the chondroprotective effect of diacerein and glucosamine regarding degenerative changes and articular stiffness in an experimental model of arthritis. METHODS: Twenty rats underwent medial meniscectomy on the right knee. Ten animals were given diacerhein, and 10 were given glucosamine, from day 1 to the third month postoperatively, when all of them were killed. Histological and functional analysis of the knees were performed (measurement of maximum extension). RESULTS: All operated knees showed more limited extension values and more degenerative changes as compared to nonoperated contralateral sides. A comparison of the two drugs showed that the degree of articular stiffness was significantly lower with diacerein, although degenerative changes were similar. CONCLUSIONS: 1) Prophylactic use of diacerein leads to lower degree of articular stiffness when compared to glucosamine; 2) The prophylactic chondroprotective effects of diacerein and glucosamine are histologically similar.


OBJETIVO: O trabalho foi realizado com o objetivo de comparar o efeito condroprotetor da diacereína em relação ao da glicosamina quanto às alterações degenerativas e à rigidez articular num modelo experimental de artrose. MÉTODOS: Vinte ratos foram submetidos à meniscectomia medial do joelho direito. Dez animais receberam diacereína, e dez glicosamina, todos do primeiro dia ao terceiro mês pós-operatório, quando foram sacrificados. Foram realizadas análise histológica e funcional (medida da extensão máxima) dos joelhos. RESULTADOS: Todos os joelhos operados apresentaram amplitude de extensão mais limitada e maiores alterações degenerativas, em relação ao lado contra-lateral não operado. Ao compararmos as duas drogas, a rigidez articular foi significantemente menor com a diacereína, e as alterações degenerativas foram semelhantes. CONCLUSÕES: 1- O uso profilático da diacereína leva à menor rigidez articular em relação a glicosamina. 2- O efeito condroprotetor profilático da diacereína é semelhante, histologicamente, ao da glicosamina.


Subject(s)
Animals , Male , Rats , Anthraquinones/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Glucosamine/therapeutic use , Osteoarthritis, Knee/drug therapy , Stifle/drug effects , Disease Models, Animal , Menisci, Tibial/drug effects , Menisci, Tibial/surgery , Menisci, Tibial/ultrastructure , Osteoarthritis, Knee/surgery , Postoperative Care , Rats, Wistar , Severity of Illness Index , Statistics, Nonparametric , Stifle/surgery , Stifle/ultrastructure , Treatment Outcome
11.
Rev. colomb. reumatol ; 7(4): 385-9, dic. 2000.
Article in Spanish | LILACS | ID: lil-295731

ABSTRACT

La osteoartritis es una enfermedad que afecta a la gran mayoria de los individuos mayores de 60 años. A pesar de los recientes avances en la etiopatogenesis y en el manejo de dicha entidad aun no contamos con tratamientos efectivos que al mismo tiempo mejoren los sintomas y detengan la evolucion de la enfermedad. Desde hace algunos años se ha venido promulgando el uso de suplementos nutricionales como parte del tratamiento, en especial del uso de la glucosamina. Las ventajas in vitro han sido demostradas tambien en varios estudios clinicos pero estos trabajos han dejado algunas dudas sobre la magnitud del efecto benefico. Esta revision que incluye los trabajos mas recientes a Octubre de 2000 sobre el uso de la glucosamina en la osteoartrosis y ofrece una vision objetiva sobre dicha opcion terapeutica. La decision final del uso de la glucosamina debe ser ajustada en forma individual no siendo posible extrapolar los resultados actuales a toda la poblacion con osteoartritis


Subject(s)
Glucosamine/therapeutic use , Osteoarthritis/diagnosis , Osteoarthritis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL